In recent years, the essential role of recombinant galectin-1 in the control of inflammation has been widely demonstrated in experimental studies for treatment of various diseases, including autoimmune encephalomyelitis (12, 13), arthritis (23, 24), hepatitis (25), autoimmune diabetes (26, 27), and ulcerative colitis (28). Here, LGALS1 is linked to ulcerative colitis.